BioSpace News Archive

INDRC announced the launch of the INDRC Conference 2022: “Artificial Intelligence Solutions for Understanding and Treatment of Neurodegenerative Disorders.” The conference will be held on September 7 and 8, 2022, in Prague, Czech Republic, under the auspices of the Czech Ministry for EU Affairs.

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that the Israeli Ministry of Health (MoH) has approved national reimbursement for CytoSorb®.

Emergent Health Corp. (OTC PINK:EMGE) announced that Director and Chief Marketing Officer Marvin Segel to appear live on the Emerging Growth Conference, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies.

Quest Diagnostics (NYSE: DGX), today announced the launch of a new obstetrics laboratory test panel designed to enable physicians to screen all eligible pregnant people easily and reliably for hepatitis C (HCV) with other laboratory tests typically ordered during early pregnancy.

Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced the U.S. Food and Drug Administration (FDA) has approved the citrate-free, high-concentration (100 mg/mL) formulation of HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab). HADLIMA will be available in pre-filled syringe and autoinjector options, and the autoinjector was specifically designed with the patient in mind

Magenta Therapeutics today announced that it has appointed Michael Vasconcelles, M.D. to its board of directors.

Oncotelic Therapeutics, Inc., developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, announced that the Company will be participating at Biotechgate Digital Partnering – a business development & licensing event - Aug 29 - Sep 2, 2022.

Oyster Point Pharma, Inc. today announced that the largest Medicare Pharmacy Benefit Manager in the United States will add TYRVAYA ® Nasal Spray on its Medicare Part D formularies, effective September 1, 2022.

Enlivex Therapeutics Ltd. today announced that the Israeli Ministry of Health (MOH) authorized the initiation of a company-sponsored Phase I/II clinical trial designed to evaluate the safety, tolerability and preliminary efficacy of Allocetra.

RedHill Biopharma today announced that the European Commission has granted Orphan Drug Designation to RHB-2041 for the treatment of nontuberculous mycobacteria (NTM) disease.